Moderna Named a Top Employer by Science for Twelfth Consecutive Year

Beyond the employer recognition, Moderna highlighted two vaccine approvals and positive topline Phase 3 melanoma results in 2026.

Rhea-AI Summary

Moderna (NASDAQ:MRNA) was named a top biopharmaceutical employer in Science and Science Careers’ survey for the twelfth consecutive year. The 2026 survey drew approximately 5,100 responses and recognized Moderna for its corporate image, leadership and direction, and work culture.

The company also highlighted its fourth and fifth product approvals: mCOMBRIAX, a combined influenza and COVID-19 vaccine, received European Union marketing authorization in April 2026; mFLUSIVA, a seasonal influenza vaccine, received FDA approval in August 2026. That August, Moderna and Merck announced positive topline results from the Phase 3 INTerpath-001 trial of investigational intismeran autogene with KEYTRUDA in patients with resected stage IIB-IV melanoma.

3 points · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

How the balance works

Positive

• Major pointPhase 3 INTerpath-001 reported positive topline results for investigational intismeran autogene with KEYTRUDA in resected stage IIB-IV melanoma.
• Moderate pointmCOMBRIAX received European Union marketing authorization in April 2026 for prevention of influenza and COVID-19.
• Moderate pointmFLUSIVA received FDA approval in August 2026 as a vaccine against seasonal influenza.

Negative

• None.

Argus 15 min delay 27 alerts

-3.77% vs previous close $195.00 last price 3.5x rel. volume Open Argus

Details

Market Reaction – MRNA

$190.25 – $201.24 Day Range

$77.85B Mkt Cap at Last Price

On Oct 23, the day this news came out, the latest delayed price for MRNA is 3.77% below the previous close. Our momentum scanner has recorded 27 alerts for this stock so far that day. The latest delayed price is $195.00. Relative volume is very high at 3.5x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Terms

mrna, phase 3, marketing authorization

3 terms

mrna technical

"advance mRNA science and translate that work into meaningful advances for patients."

mRNA, short for messenger ribonucleic acid, is a biological molecule that carries instructions from a cell’s genetic blueprint to make specific proteins — like a recipe or software code that tells a kitchen or computer what to produce. Investors care because mRNA is used as a flexible drug and vaccine platform that can be developed and scaled faster than many traditional medicines; its commercial prospects, manufacturing needs, regulatory approval path, and patent position can strongly affect a company’s value.

phase 3 medical

"positive topline results from the Phase 3 INTerpath-001 trial"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

marketing authorization regulatory

"was granted marketing authorization in the European Union in April 2026."

An official government approval that allows a drug, vaccine, or medical device to be sold and promoted in a specific country or region. Think of it as a safety and effectiveness passport issued after regulators review the product’s tests and manufacturing; for investors, receiving this authorization typically unlocks sales, revenue potential, and lower regulatory risk, while delays or denials can substantially affect a company’s value and timeline.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2026 Top Employers Survey for the twelfth consecutive year. Moderna was recognized for its corporate image, leadership and direction, and work culture, reflecting its reputation for innovation and quality research, commitment to continuous improvement, and collaborative, data-driven environment.

"At Moderna, we have always believed that the best science happens when talented people are given the opportunity to tackle important problems and make an impact," said Stéphane Bancel, Chief Executive Officer of Moderna. "To be recognized by Science for twelve consecutive years is a testament to the thousands of people who have helped build and evolve this company. What continues to unite us is a shared determination to advance mRNA science and translate that work into meaningful advances for patients."

In 2026, Moderna received approval for its fourth and fifth products. mCOMBRIAX®, the Company's mRNA combination vaccine for the prevention of influenza disease and COVID-19 caused by SARS-CoV-2 was granted marketing authorization in the European Union in April 2026. mFLUSIVA®, a new vaccine against seasonal influenza was approved by the U.S. Food and Drug Administration in August 2026. In August 2026, Moderna and Merck announced positive topline results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene, an investigational individualized mRNA cancer therapy, in combination with KEYTRUDA® in patients with resected stage IIB-IV melanoma. As part of Moderna's ongoing commitment to social responsibility, the Company also marked the fourth anniversary of the Moderna Charitable Foundation and issued its fifth annual Impacting Human Health Report.

"Being a top employer starts with the strength of our people and what we can accomplish together," said Tracey Franklin, Chief People and Digital Technology Officer of Moderna. "We are building an organization that brings together the expertise of our people with digital capabilities and AI to solve complex problems in new ways and create an even greater impact for patients."

For more than 20 years, Science has surveyed its readership to identify and celebrate the top 20 pharmaceutical and biotechnology companies with the best reputation as employers. The 2026 survey's findings are based on approximately 5,100 completed surveys from readers of Science, and other survey invitees. A vast majority of the survey participants came from North America (71%), Europe (19%), and Asia/Pacific Rim (6%).

For the complete feature along with individual company rankings, please visit: https://www.science.org/content/article/2026-s-top-employers-ai-i-do

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including pioneering work on COVID-19 vaccines.

Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Moderna Contacts

Media:
Chris Ridley
VP, Global Head of Communications
+1 617-800-3651
Chris.Ridley@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View the original press release on ACCESS Newswire